PHRR230203-005387
Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)
An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab (MK-3475) in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater Than or Equal to 50% Metastatic Non-small Cell Lung Cancer (KEYNOTE D46/EVOKE-03)
Merck Sharp & Dohme (I.A.) LLC·Phase 3·Philippine Health Research RegistryOngoing
Study focus
- Disease/Condition
- Carcinoma, Non-Small-Cell Lung
- Study type
- Interventional
Sponsor & location
- Primary sponsor
- Merck Sharp & Dohme (I.A.) LLC
- Location
- Australia;Brazil;Canada;Chile;China;Estonia;Germany;Greece;Israel;Italy;Japan;Latvia;Lithuania;Malay
Timeline & enrollment
- Phase
- Phase 3
- Start date
- Jul 11, 2023
- End date
- N/A
ICD-10 classifications
Carcinoma in situ: Bronchus and lungSecondary malignant neoplasm of lungMalignant neoplasm: Lower lobe, bronchus or lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm of bronchus and lung
Data source
- Registry
- Philippine Health Research Registry
- Trial ID
- PHRR230203-005387
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for PHRR230203-005387 through Pure Global AI's free database. This Phase 3 trial is sponsored by Merck Sharp & Dohme (I.A.) LLC and is currently Ongoing. The study focuses on Carcinoma, Non-Small-Cell Lung.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Philippine Health Research Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.